Wellington Management Group LLP lifted its stake in shares of Pharvaris N.V. (NASDAQ:PHVS – Free Report) by 12.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 2,392,934 shares of the company’s stock after buying an additional 274,034 shares during the quarter. Wellington Management Group LLP’s holdings in Pharvaris were worth $82,748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently modified their holdings of PHVS. Quantbot Technologies LP purchased a new position in Pharvaris in the 2nd quarter valued at $41,000. JPMorgan Chase & Co. increased its stake in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. Barclays PLC purchased a new position in Pharvaris during the 4th quarter worth $77,000. CoreCap Advisors LLC purchased a new position in Pharvaris during the 2nd quarter worth $93,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Pharvaris in the 4th quarter worth $110,000.
Analyst Ratings Changes
Several brokerages have recently weighed in on PHVS. Guggenheim lifted their target price on shares of Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Citizens Jmp raised their price objective on shares of Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a research report on Thursday, August 13th. Morgan Stanley boosted their target price on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Finally, HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.08.
Insider Activity at Pharvaris
In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $34.77, for a total value of $79,692.84. Following the sale, the chief executive officer owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director directly owned 315,167 shares in the company, valued at $11,185,276.83. This trade represents a 8.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 118,655 shares of company stock valued at $4,188,002 in the last ninety days. Corporate insiders own 11.84% of the company’s stock.
Pharvaris Trading Up 0.7%
Shares of PHVS opened at $35.17 on Thursday. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $38.13. The firm has a market capitalization of $2.30 billion, a P/E ratio of -11.53 and a beta of -2.33. The firm’s 50-day moving average is $34.71 and its two-hundred day moving average is $30.94.
Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Analysts predict that Pharvaris N.V. will post -3.15 EPS for the current year.
Pharvaris Company Profile
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Articles
- Five stocks we like better than Pharvaris
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding PHVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharvaris N.V. (NASDAQ:PHVS – Free Report).
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
